Sentinel Oncology is pleased to announce the recent award from Innovate UK for the development of a new drug to treat Fragile X syndrome
The award will help fund the development of a drug to treat the single largest cause of genetically inherited intellectual disability amongst diseases categorised within the autism spectrum disorders.
The award of £943,160 will help fund the development of a new small molecule drug designed to treat the underlying cause of the disease rather than the symptoms and will potentially provide additional cost savings in terms of reduced needs for ongoing care and education assistance.
Bob Boyle, CEO of Sentinel Oncology said “with this additional funding from Innovate UK Sentinel Oncology will be able to proceed to develop an exciting and potentially breakthrough new product for the treatment of Fragile X patients.”
About Sentinel Oncology Limited
Sentinel Oncology was founded in 2005 in Cambridge, UK and is a drug discovery company dedicated to the development and commercialisation of new therapeutics to treat cancer patients for whom there is currently an unmet medical need.
The Sentinel Oncology portfolio includes a lead programme that has been licensed to Oncothyreon Inc. and a second programme which is at the candidate drug phase. We are further developing a suite of novel small molecules designed to enhance therapeutic index by delivering the effects of drugs directly to the tumour.
Sentinel oncology is a fully integrated drug discovery company seeking to develop high quality drug candidates for partnering with the biotechnology and pharmaceutical industry. Our strategy relies on seeking partners and collaborators to maximise the value of our programmes.
About Innovate UK
Innovate UK is the UK’s innovation agency. It works with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy.
For further information visit www.innovateuk.gov.uk
About the Biomedical Catalyst
The Biomedical Catalyst, announced by Prime Minister David Cameron in December 2011, is a £180 million programme of public funding designed to deliver growth to the UK life sciences sector. Delivered jointly by the Medical Research Council and the Technology Strategy Board, the Biomedical Catalyst provides responsive and effective support for the best life science opportunities arising in the UK.